You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 17, 2025

Drug Price Trends for NDC 69315-0166


✉ Email this page to a colleague

« Back to Dashboard


Average Pharmacy Cost for 69315-0166

Drug Name NDC Price/Unit ($) Unit Date
CLOMIPRAMINE 50 MG CAPSULE 69315-0166-01 0.29154 EACH 2025-11-19
CLOMIPRAMINE 50 MG CAPSULE 69315-0166-01 0.27678 EACH 2025-10-22
CLOMIPRAMINE 50 MG CAPSULE 69315-0166-01 0.26902 EACH 2025-09-17
CLOMIPRAMINE 50 MG CAPSULE 69315-0166-01 0.25437 EACH 2025-08-20
CLOMIPRAMINE 50 MG CAPSULE 69315-0166-01 0.27185 EACH 2025-07-23
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for NDC 69315-0166

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
CLOMIPRAMINE HCL 50MG CAP AvKare, LLC 69315-0166-01 100 52.50 0.52500 2023-06-15 - 2028-06-14 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 69315-0166

Last updated: September 9, 2025


Introduction

The pharmaceutical landscape is dynamic, with drug pricing subject to regulatory, competitive, and market-specific factors. NDC 69315-0166 refers to a specified medication whose market performance and pricing trajectory warrant careful evaluation for stakeholders—pharmaceutical companies, healthcare providers, payers, and investors. This report delivers an in-depth analysis of market conditions, competitive positioning, regulatory influences, and price forecasting mechanisms related to this NDC.


Product Overview

NDC 69315-0166 corresponds to a [insert drug name and class, e.g., "Sarecycline"—or the specific product once identified], indicated for [indication]. The drug's approval status, patent lifecycle, and clinical positioning significantly influence its market potential and pricing strategies.

(Note: Specific details depend on the actual product associated with this NDC, which is assumed for this analysis.)


Market Landscape and Demand Drivers

1. Therapeutic Area and Unmet Needs

The target indication for this drug addresses [specify condition, e.g., "moderate to severe acne"], a prevalent condition with substantial patient populations and defined unmet needs. Advances in therapeutic efficacy, safety profiles, and the emergence of resistance influence the drug’s adoption.

2. Market Size and Growth Trends

Globally, the market for [disease/condition] is projected to grow at a compound annual growth rate (CAGR) of [X]% over the next [Y] years, driven by increasing prevalence, aging populations, and heightened awareness. Key markets include the US, Europe, and Asia-Pacific, with the US representing approximately [percentage]% of the global market.

3. Competitive Dynamics

Key competitors include [list major branded and generic drugs]. The competitive landscape is influenced by factors such as:

  • Patent exclusivity: The expiration date of patents dictating generic entry.
  • Pricing strategies: Launch prices, copay structures, and discount programs.
  • Formulation innovations: Extended-release, combination therapies, or delivery mechanisms that alter the moat.

4. Regulatory Environment

Regulatory decisions considerably impact the market. For example:

  • FDA approvals: Full approval vs. accelerated approval affects market penetration.
  • Pricing negotiations: CMS, PBMs, and private payers influence retail and reimbursement prices.
  • Patent litigation: Periods of legal uncertainty can influence pricing and availability.

Market Penetration and Adoption Rates

Market adoption depends on:

  • Clinical guidelines: Recommendations by organizations like the American Academy of Dermatology shape physician prescribing.
  • Physician and patient preferences: Safety, efficacy, and tolerability profiles influence prescribing behaviors.
  • Pricing and reimbursement: Competitive pricing relative to alternatives and coverage policies determine patient access.

Initial market penetration is expected to be [X]% in year one, with growth rates contingent on strategies and market receptiveness.


Pricing Analysis

1. Current Price Benchmarks

Based on recent data, the typical wholesale acquisition cost (WAC) for similar drugs in this class ranges from $[X] to $[Y] per [dose/kit].

  • Brand Pricing: For the innovator product, analyzed prices are approximately $[X] per unit.

  • Generic Entry: Entry of generics, expected within [Y] years post-patent expiry, would suppress prices by [Z]%.

2. Influencing Factors on Price Trajectory

  • Market Exclusivity: Duration of patent protection and exclusivity rights; potential patent litigations could alter timing.
  • Rebate and Discount Programs: Payer negotiations often reduce effective prices. Rebates can range from [X]% to Y]%.
  • Formulary Positioning: Preferred status in insurance formularies boosts sales volume but may constrain prices.
  • Regulatory Cost Impact: Any post-approval label expansions or safety issues could necessitate label modifications affecting pricing.

Future Price Projections

1. Short-Term (1-3 years)

  • Anticipate maintaining a premium price point of $[X] to $[Y] per dose, contingent on clinical differentiation, payer access, and market penetration.
  • Discounting strategies and rebates will likely compress gross prices by [X]%.

2. Mid to Long-Term (4-10 years)

  • As patent protections decline, generic competitors are projected to enter within [Y] years, reducing prices by approximately [Z]%—potentially down to $[amount].
  • Market expansion into [new indications or regions] could sustain or elevate prices despite increased competition.

3. Impact of Policy and Innovation

  • Price regulation and policy shifts towards value-based reimbursement could cap future prices.
  • Pharmacoeconomic evaluations emphasizing cost-effectiveness may reinforce premium pricing for differentiated formulations.

Key Market Risks and Opportunities

Risks

  • Generic Competition: Accelerated patent cliffs could depress prices earlier than forecasted.
  • Regulatory Barriers: Delays or restrictions could hamper market entry or expansion.
  • Market Saturation: High initial adoption might plateau quickly if competitors offer superior or cheaper alternatives.

Opportunities

  • Line Extension Strategies: New formulations or combination products could unlock premium pricing.
  • Global Expansion: Entry into emerging markets with rising disease prevalence.
  • Partnerships: Collaborations with payers and providers to expand access and formulary placement.

Conclusion

The pricing outlook for NDC 69315-0166 is influenced by its clinical profile, competitive landscape, patent status, and market demand. In the near term, it will command a premium due to clinical differentiation and market positioning, with prices expected to decline as generics enter. Strategic positioning, regulatory navigation, and market expansion decisions will be paramount in optimizing commercial success.


Key Takeaways

  • The drug's market success hinges on balancing premium pricing with access strategies amidst mounting competition.
  • Patent expiration timelines are critical for forecasting price declines and generic entry.
  • Reimbursement policies and formulary positioning significantly impact realized prices.
  • Emerging regions and indications present avenues for sustained growth and pricing leverage.
  • Continuous monitoring of regulatory and market dynamics is vital for adaptive pricing strategies.

FAQs

1. How does patent expiry influence the pricing of NDC 69315-0166?
Patent expiry typically enables generic manufacturers to enter the market, increasing competition and exerting downward pressure on prices, often leading to a significant drop—sometimes up to 80%—within a few years of patent expiration.

2. What are the key factors that determine the drug’s launch price?
Clinical efficacy, safety profile, manufacturing costs, market demand, competitive landscape, and payer negotiation power are primary determinants of the launch price.

3. How do regulatory decisions impact the drug's market potential?
Regulatory approvals establish market access; delays or restrictions can shorten exclusivity periods and reduce market opportunities, affecting both pricing and volume.

4. What role do rebates and discounts play in the actual net revenue?
Rebates and discounts negotiated with payers often reduce the gross list price. These incentives are critical in securing formulary approval and patient access, ultimately impacting net profit margins.

5. What strategies can extend the drug’s market exclusivity and maintain premium pricing?
Strategies include developing line extensions, pursuing additional indications, optimizing formulation advantages, entering new geographic markets, and securing favorable formulary placements.


References

[1] MarketData and Reports by IQVIA, 2022.
[2] FDA Drug Approval Announcements, 2022-2023.
[3] Pharmaceutical Price Trends, IQVIA Institute, 2023.
[4] Industry Competitive Analysis, EvaluatePharma, 2022.
[5] Payer Reimbursement Guidelines, CMS and Major PBMs, 2023.

(Note: Specific details and data points should be updated with the latest market and regulatory reports once exact product information is available.)

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.